vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and Porch Group, Inc. (PRCH). Click either name above to swap in a different company.

Porch Group, Inc. is the larger business by last-quarter revenue ($121.1M vs $85.1M, roughly 1.4× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -3.9%, a 26.7% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 100.0%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 26.4%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

Porch is a website that tries to connect homeowners with local home improvement contractors. The site features advice articles, cost guide, and online booking for over 160 home projects.

FDMT vs PRCH — Head-to-Head

Bigger by revenue
PRCH
PRCH
1.4× larger
PRCH
$121.1M
$85.1M
FDMT
Growing faster (revenue YoY)
FDMT
FDMT
+8508800.0% gap
FDMT
8508900.0%
100.0%
PRCH
Higher net margin
FDMT
FDMT
26.7% more per $
FDMT
22.8%
-3.9%
PRCH
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
26.4%
PRCH

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FDMT
FDMT
PRCH
PRCH
Revenue
$85.1M
$121.1M
Net Profit
$19.4M
$-4.7M
Gross Margin
52.7%
Operating Margin
17.3%
34.7%
Net Margin
22.8%
-3.9%
Revenue YoY
8508900.0%
100.0%
Net Profit YoY
139.1%
2.0%
EPS (diluted)
$0.43
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
PRCH
PRCH
Q1 26
$121.1M
Q4 25
$85.1M
$112.3M
Q3 25
$90.0K
$115.1M
Q2 25
$15.0K
$107.0M
Q1 25
$14.0K
$84.5M
Q4 24
$1.0K
$75.3M
Q3 24
$3.0K
$77.7M
Q2 24
$5.0K
$75.9M
Net Profit
FDMT
FDMT
PRCH
PRCH
Q1 26
$-4.7M
Q4 25
$19.4M
$-3.5M
Q3 25
$-56.9M
$-10.9M
Q2 25
$-54.7M
$2.6M
Q1 25
$-48.0M
$8.4M
Q4 24
$30.5M
Q3 24
$-43.8M
$14.4M
Q2 24
$-35.0M
$-64.3M
Gross Margin
FDMT
FDMT
PRCH
PRCH
Q1 26
52.7%
Q4 25
99.5%
Q3 25
75.6%
Q2 25
70.9%
Q1 25
77.4%
Q4 24
Q3 24
79.4%
Q2 24
22.1%
Operating Margin
FDMT
FDMT
PRCH
PRCH
Q1 26
34.7%
Q4 25
17.3%
14.7%
Q3 25
-67983.3%
14.2%
Q2 25
-396373.3%
4.7%
Q1 25
-383007.1%
-1.5%
Q4 24
33.3%
Q3 24
-1704400.0%
-3.2%
Q2 24
-849120.0%
-69.2%
Net Margin
FDMT
FDMT
PRCH
PRCH
Q1 26
-3.9%
Q4 25
22.8%
-3.1%
Q3 25
-63195.6%
-9.4%
Q2 25
-364386.7%
2.4%
Q1 25
-342657.1%
9.9%
Q4 24
40.5%
Q3 24
-1461433.3%
18.5%
Q2 24
-699060.0%
-84.8%
EPS (diluted)
FDMT
FDMT
PRCH
PRCH
Q1 26
$-0.04
Q4 25
$0.43
$0.00
Q3 25
$-1.01
$-0.10
Q2 25
$-0.98
$0.00
Q1 25
$-0.86
$0.07
Q4 24
$0.34
Q3 24
$-0.79
$0.12
Q2 24
$-0.63
$-0.65

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
PRCH
PRCH
Cash + ST InvestmentsLiquidity on hand
$402.7M
$68.4M
Total DebtLower is stronger
$391.3M
Stockholders' EquityBook value
$505.7M
$26.3M
Total Assets
$566.7M
$806.6M
Debt / EquityLower = less leverage
14.87×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
PRCH
PRCH
Q1 26
$68.4M
Q4 25
$402.7M
$57.3M
Q3 25
$305.1M
$85.0M
Q2 25
$293.2M
$79.8M
Q1 25
$321.4M
$70.4M
Q4 24
$424.9M
$191.7M
Q3 24
$501.9M
$238.6M
Q2 24
$541.9M
$308.4M
Total Debt
FDMT
FDMT
PRCH
PRCH
Q1 26
$391.3M
Q4 25
$392.8M
Q3 25
$387.1M
Q2 25
$394.1M
Q1 25
$409.2M
Q4 24
$403.9M
Q3 24
$399.0M
Q2 24
$436.8M
Stockholders' Equity
FDMT
FDMT
PRCH
PRCH
Q1 26
$26.3M
Q4 25
$505.7M
$-24.6M
Q3 25
$369.0M
$-27.9M
Q2 25
$420.9M
$-29.3M
Q1 25
$469.7M
$-52.4M
Q4 24
$510.6M
$-43.2M
Q3 24
$552.9M
$-77.0M
Q2 24
$588.3M
$-101.9M
Total Assets
FDMT
FDMT
PRCH
PRCH
Q1 26
$806.6M
Q4 25
$566.7M
$797.4M
Q3 25
$424.0M
$787.7M
Q2 25
$473.6M
$770.7M
Q1 25
$515.7M
$802.3M
Q4 24
$560.4M
$814.0M
Q3 24
$604.0M
$867.3M
Q2 24
$620.1M
$876.1M
Debt / Equity
FDMT
FDMT
PRCH
PRCH
Q1 26
14.87×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
PRCH
PRCH
Operating Cash FlowLast quarter
$28.6M
Free Cash FlowOCF − Capex
$28.5M
FCF MarginFCF / Revenue
33.5%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
PRCH
PRCH
Q1 26
Q4 25
$28.6M
$1.2M
Q3 25
$-46.5M
$40.8M
Q2 25
$-43.4M
$35.6M
Q1 25
$-47.8M
$-11.2M
Q4 24
$-134.6M
$-26.6M
Q3 24
$-29.4M
$12.4M
Q2 24
$-30.2M
$-26.0M
Free Cash Flow
FDMT
FDMT
PRCH
PRCH
Q1 26
Q4 25
$28.5M
$1.1M
Q3 25
$-46.6M
$40.7M
Q2 25
$-43.4M
$35.4M
Q1 25
$-48.4M
$-11.2M
Q4 24
$-138.4M
$-26.8M
Q3 24
$-31.2M
$12.2M
Q2 24
$-30.6M
$-26.0M
FCF Margin
FDMT
FDMT
PRCH
PRCH
Q1 26
Q4 25
33.5%
1.0%
Q3 25
-51765.6%
35.4%
Q2 25
-289620.0%
33.0%
Q1 25
-345635.7%
-13.3%
Q4 24
-13837100.0%
-35.6%
Q3 24
-1038966.7%
15.7%
Q2 24
-611840.0%
-34.3%
Capex Intensity
FDMT
FDMT
PRCH
PRCH
Q1 26
Q4 25
0.1%
0.1%
Q3 25
101.1%
0.1%
Q2 25
440.0%
0.2%
Q1 25
4507.1%
0.1%
Q4 24
378600.0%
0.3%
Q3 24
59266.7%
0.3%
Q2 24
6980.0%
0.1%
Cash Conversion
FDMT
FDMT
PRCH
PRCH
Q1 26
Q4 25
1.47×
Q3 25
Q2 25
13.79×
Q1 25
-1.33×
Q4 24
-0.87×
Q3 24
0.86×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons